Improvement of fibroid-associated symptoms and quality of life after US-guided high-intensity focused ultrasound (HIFU) of uterine fibroids
-
Published:2022-12-07
Issue:1
Volume:12
Page:
-
ISSN:2045-2322
-
Container-title:Scientific Reports
-
language:en
-
Short-container-title:Sci Rep
Author:
Tonguc Tolga,Recker Florian,Ganslmeier Judith,Strunk Holger M.,Pieper Claus C.,Ramig Olga,Welz Simone,Egger Eva K.,Mutschler Nikola,Warwas Leonie,Essler Markus,Mustea Alexander,Conrad Rupert,Marinova Milka
Abstract
AbstractUterine fibroids are the most common benign uterine tumors and can cause various severe symptoms as abnormal menstrual bleeding or pelvic pain. Therefore, the primary objective in the treatment of uterine fibroids is a sufficient symptom relief. Ultrasound (US)-guided High-intensity focused ultrasound (HIFU) is an effective non-invasive treatment strategy for ablation of uterine fibroids that can achieve a significant tumor volume reduction. The aim of the study is to evaluate if US-guided HIFU treatment can reduce fibroid-associated symptoms leading to an improvement of health-related quality of life. Fifty-five women with symptomatic uterine fibroids underwent US-guided HIFU ablation. Clinical evaluation was performed on the basis of the Uterine Fibroid Symptom and Health-Related Quality of Life Questionnaire (UFS-QOL) at baseline, 6 weeks, 3, 6, 9 and 12 months after HIFU. Imaging follow-up included contrast-enhanced ultrasound (CEUS) and contrast-enhanced MRI. A significant reduction of the Symptom Severity Scale (SSS) was observed between 6 weeks and 12 months after HIFU (49.9 ± 19.4 at baseline vs. 42.2 ± 20.1 at 6 weeks and 23.6 ± 12.7 at 12 months after treatment, p < 0.001) correlating with a significant improvement (p < 0.001) of Health-related Quality of Life (HRQL) (52.5 ± 22.7 at baseline vs. 59.8 ± 22 at 6 weeks and 77.9 ± 17.3 at 12 months after treatment). Significant postinterventional improvement was observed in every subscale of HRQL. In the majority of patients, only minor, short-lasting and self-limiting side effects were observed, e.g. soft tissue edema of the anterior lower abdominal wall in the acoustic pathway or transient moderate lower abdominal pain as during menstruation. One patient with a very large fibroid experienced strong short-lasting pain after the procedure; two patients experienced post-procedurally a transient sciatic nerve irritation. US-guided HIFU of uterine fibroids reduces disease-related symptoms and improves health-related quality of life.
Funder
Universitätsklinikum Bonn
Publisher
Springer Science and Business Media LLC
Subject
Multidisciplinary
Reference40 articles.
1. Stewart, E. A., Cookson, C. L., Gandolfo, R. A. & Schulze-Rath, R. Epidemiology of uterine fibroids: A systematic review. BJOG 124, 1501–1512 (2017). 2. Baird, D. D., Dunson, D. B., Hill, M. C., Cousins, D. & Schectman, J. M. High cumulative incidence of uterine leiomyoma in black and white women: Ultrasound evidence. Am. J. Obstet. Gynecol. 188, 100–107 (2003). 3. Zimmermann, A., Bernuit, D., Gerlinger, C., Schaefers, M. & Geppert, K. Prevalence, symptoms and management of uterine fibroids: An international internet-based survey of 21,746 women. BMC Women’s Health 12, 6 (2012). 4. Boosz, A. S., Reimer, P., Matzko, M., Römer, T. & Müller, A. The conservative and interventional treatment of fibroids. Dtsch. Arztebl. Int. 111, 877–883 (2014). 5. Donnez, J. & Dolmans, M.-M. Uterine fibroid management: From the present to the future. Hum. Reprod. Update 22, 665–686 (2016).
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|